110 related articles for article (PubMed ID: 27458663)
1. Anticalins directed against vascular endothelial growth factor receptor 3 (VEGFR-3) with picomolar affinities show potential for medical therapy and in vivo imaging.
Richter A; Skerra A
Biol Chem; 2017 Jan; 398(1):39-55. PubMed ID: 27458663
[TBL] [Abstract][Full Text] [Related]
2. Selection and characterization of Anticalins targeting human prostate-specific membrane antigen (PSMA).
Barinka C; Ptacek J; Richter A; Novakova Z; Morath V; Skerra A
Protein Eng Des Sel; 2016 Mar; 29(3):105-15. PubMed ID: 26802163
[TBL] [Abstract][Full Text] [Related]
3. Structural and mechanistic insights into VEGF receptor 3 ligand binding and activation.
Leppänen VM; Tvorogov D; Kisko K; Prota AE; Jeltsch M; Anisimov A; Markovic-Mueller S; Stuttfeld E; Goldie KN; Ballmer-Hofer K; Alitalo K
Proc Natl Acad Sci U S A; 2013 Aug; 110(32):12960-5. PubMed ID: 23878260
[TBL] [Abstract][Full Text] [Related]
4. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
[TBL] [Abstract][Full Text] [Related]
5. RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways.
Feng Y; Hu J; Ma J; Feng K; Zhang X; Yang S; Wang W; Zhang J; Zhang Y
Eur J Cancer; 2011 Oct; 47(15):2353-63. PubMed ID: 21680174
[TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor (VEGF)/VEGF-C mosaic molecules reveal specificity determinants and feature novel receptor binding patterns.
Jeltsch M; Karpanen T; Strandin T; Aho K; Lankinen H; Alitalo K
J Biol Chem; 2006 Apr; 281(17):12187-95. PubMed ID: 16505489
[TBL] [Abstract][Full Text] [Related]
7. Identification of high-affinity VEGFR3-binding peptides through a phage-displayed random peptide library.
Shi LF; Wu Y; Li CY
J Gynecol Oncol; 2015 Oct; 26(4):327-35. PubMed ID: 26197772
[TBL] [Abstract][Full Text] [Related]
8. Structural determinants of vascular endothelial growth factor-D receptor binding and specificity.
Leppänen VM; Jeltsch M; Anisimov A; Tvorogov D; Aho K; Kalkkinen N; Toivanen P; Ylä-Herttuala S; Ballmer-Hofer K; Alitalo K
Blood; 2011 Feb; 117(5):1507-15. PubMed ID: 21148085
[TBL] [Abstract][Full Text] [Related]
9. Anticalins small engineered binding proteins based on the lipocalin scaffold.
Gebauer M; Skerra A
Methods Enzymol; 2012; 503():157-88. PubMed ID: 22230569
[TBL] [Abstract][Full Text] [Related]
10. Combinatorial design of an Anticalin directed against the extra-domain b for the specific targeting of oncofetal fibronectin.
Gebauer M; Schiefner A; Matschiner G; Skerra A
J Mol Biol; 2013 Feb; 425(4):780-802. PubMed ID: 23238252
[TBL] [Abstract][Full Text] [Related]
11. Differential expression of VEGF ligands and receptors in prostate cancer.
Woollard DJ; Opeskin K; Coso S; Wu D; Baldwin ME; Williams ED
Prostate; 2013 May; 73(6):563-72. PubMed ID: 23038639
[TBL] [Abstract][Full Text] [Related]
12. Anticalins Reveal High Plasticity in the Mode of Complex Formation with a Common Tumor Antigen.
Schiefner A; Gebauer M; Richter A; Skerra A
Structure; 2018 Apr; 26(4):649-656.e3. PubMed ID: 29526433
[TBL] [Abstract][Full Text] [Related]
13. High-affinity Anticalins with aggregation-blocking activity directed against the Alzheimer β-amyloid peptide.
Rauth S; Hinz D; Börger M; Uhrig M; Mayhaus M; Riemenschneider M; Skerra A
Biochem J; 2016 Jun; 473(11):1563-78. PubMed ID: 27029347
[TBL] [Abstract][Full Text] [Related]
14. Vascular endothelial growth factor C stimulates progression of human gastric cancer via both autocrine and paracrine mechanisms.
Kodama M; Kitadai Y; Tanaka M; Kuwai T; Tanaka S; Oue N; Yasui W; Chayama K
Clin Cancer Res; 2008 Nov; 14(22):7205-14. PubMed ID: 19010837
[TBL] [Abstract][Full Text] [Related]
15. Foretinib inhibits angiogenesis, lymphangiogenesis and tumor growth of pancreatic cancer in vivo by decreasing VEGFR-2/3 and TIE-2 signaling.
Chen HM; Tsai CH; Hung WC
Oncotarget; 2015 Jun; 6(17):14940-52. PubMed ID: 25909285
[TBL] [Abstract][Full Text] [Related]
16. Suppression of lymphangiogenesis by soluble vascular endothelial growth factor receptor-2 in a mouse lung cancer model.
Maehana S; Nakamura M; Ogawa F; Imai R; Murakami R; Kojima F; Majima M; Kitasato H
Biomed Pharmacother; 2016 Dec; 84():660-665. PubMed ID: 27697638
[TBL] [Abstract][Full Text] [Related]
17. Alternative binding proteins: anticalins - harnessing the structural plasticity of the lipocalin ligand pocket to engineer novel binding activities.
Skerra A
FEBS J; 2008 Jun; 275(11):2677-83. PubMed ID: 18435758
[TBL] [Abstract][Full Text] [Related]
18. Effective suppression of vascular network formation by combination of antibodies blocking VEGFR ligand binding and receptor dimerization.
Tvorogov D; Anisimov A; Zheng W; Leppänen VM; Tammela T; Laurinavicius S; Holnthoner W; Heloterä H; Holopainen T; Jeltsch M; Kalkkinen N; Lankinen H; Ojala PM; Alitalo K
Cancer Cell; 2010 Dec; 18(6):630-40. PubMed ID: 21130043
[TBL] [Abstract][Full Text] [Related]
19. Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth.
Laakkonen P; Waltari M; Holopainen T; Takahashi T; Pytowski B; Steiner P; Hicklin D; Persaud K; Tonra JR; Witte L; Alitalo K
Cancer Res; 2007 Jan; 67(2):593-9. PubMed ID: 17234768
[TBL] [Abstract][Full Text] [Related]
20. [Expression and clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in non-small cell lung carcinoma].
Lu ZQ; Li HG; Xie DR; Zhang HZ; Shen XM; Zeng YJ; Zeng H
Ai Zheng; 2005 Sep; 24(9):1132-5. PubMed ID: 16159440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
